George W. Bickerstaff, Chairman

Former CFO of Novartis Pharma AG. Instrumental in establishing the strategic, operating and financial direction of numerous private and public companies. Provided financial leadership for mergers and acquisitions valued at more than $50 billion and has funded and operated various venture capital businesses. Currently Managing Director of M.M. Dillon & Co. View Biography >>

Terence A. Kelly, Ph.D., Director

Nearly 20 years in scientific and executive positions at Boehringer Ingelheim, including VP, Department of Medicinal Chemistry; led 145 scientists in the high throughput screening, computational chemistry, structural biology, combinatorial chemistry and medicinal chemistry groups. Currently President and CEO of CoMentis, Inc. View Biography >>

Michele Galen, Director

Broad and deep global healthcare experience across pharmaceuticals, consumer health, biotechnology and health start-ups working as a strategic advisor to senior management and boards for over two decades. Served as Chief Communications Officer for Novartis AG and Shire plc, with extensive experience in transactional and financial communications. Currently serving as a strategic advisor and board member to diverse healthcare firms and nonprofits. Experienced lawyer and former business journalist. View Biography >>

David G. Watumull, Director

More than twenty years experience as a biotechnology industry executive, analyst, and investment banker. Co-founder of Cardax and co-inventor of Cardax technology. As CEO of Hawaii Biotech, led efforts that raised more than $25 million in equity financing and $30 million in grant funding. Started and led a West Nile virus vaccine program at Hawaii Biotech that achieved success in a human proof of concept study. View Biography >>